Abstract:OBJECTIVE To approach the species of pathogenic bacteria causing nosocomial infections in the patients with severe hepatitis and liver cirrhosis and analyze the drug resistance so as to provide guidance clinical use of an-tibiotics .METHODS The clinical data of 251 severe hepatitis and liver cirrhosis patients complicated with secondary nosocomial infections were reviewed ,then the isolation ,culture ,and identification of the pathogens were per-formed by referring to the criteria of clinical microorganism laboratory examination ;the drug susceptibility testing was performed by using K-B method ,the drug susceptibility ,intermediate ,and resistance were determined ac-cording to the latest breakpoints of CLSI ,and the whole process of examination was carried out under the qualified indoor quality control .RESULTS Among the patients with severe hepatitis and liver cirrhosis ,the patients with ab-dominal infections accounted for 27 .6% ,the patients with respiratory tract infections 19 .2% ,the patients with urinary tract infections 16 .9% .A total of 195 strains of pathogens have been isolated ,including 195 (70 .1% ) strains of gram-negative bacteria ,60 (21 .6% ) strains of gram-positive bacteria and 23 (8 .3% ) strains of fungi;the Escherichia coli ,Enterococcus ,K lebsiella pneumoniae ,and Pseudomonas aeruginosa ranked the top four spe-cies of pathogens ,accounting for 23 .4% ,17 .6% ,16 .9% ,and 11 .9% ,respectively .The drug susceptibility rates of the E .coli and K .pneumoniae to imipenem and meropenem were 100 .0% ,and the drug resistance rates to cefoperazone-sulbactam and amikacin were less than 15 .4% ;the drug resistance rates of the P .aeruginosa to pip-eracillin-tazobactam and cefoperazone-sulbactam were less than 18 .2% .The isolation rates of the imipenem-resist-ant P .aeruginosa and Acinetobacter baumannii were 38 .5% and 33 .3% ,respectively ;the isolation rates of the extended-spectrum β-lactamases (ESBLs)-producing E .coli and K .pneumoniae were 56 .3% ;the isolation rate of the methicillin-resistant Staphylococcus was 54 .5% .CONCLUSION It is the key for the treatment of the patients with severe hepatitis and liver cirrhosis to perform early intervention and effectively control the nosocomial infec-tions ,and the study suggests that it is necessary to reduce invasive medical procedures and implement the compre-hensive intervention so as to raise the clinical cure rate and extend the life span of the patients with severe hepatitis and liver cirrhosis .

The challenges of multi-drug-resistance in hepatology

The Spread of Multi Drug Resistant Infections Is Leading to an Increase in the Empirical Antibiotic Treatment Failure in Cirrhosis: A Prospective Survey

Antibiotic prophylaxis in cirrhosis: Good and bad

Drug resistance of pathogens causing nosocomial infections in patients with severe hepatitis and liver cirrhosis

Multidrug-resistant bacterial infections in cirrhotic patients: an epidemiological study.

Antimicrobial Multidrug Resistance: Clinical Implications for Infection Management in Critically Ill Patients

Prevalence and predictors of multidrug-resistant bacteremia in liver cirrhosis

Multidrug-resistant bacterial infections in the liver transplant setting

Infections complicating cirrhosis

New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties

Terlipressin therapy is associated with increased risk of colonisation with multidrug‐resistant bacteria in patients with decompensated cirrhosis

Multidrug-resistant Gram-negative bacteria: how to treat and for how long

OP-4 DEVELOPMENT AND EXTERNAL VALIDATION OF A MODEL TO PREDICT MULTI-DRUG RESISTANT BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS

Therapeutic Strategies to Combat Increasing Rates of Multidrug Resistant Pathogens

Fighting Antibiotic Resistance in Hospital-Acquired Infections: Current State and Emerging Technologies in Disease Prevention, Diagnostics and Therapy

New tools to mitigate drug resistance in Enterobacteriaceae – Escherichia coli and Klebsiella pneumoniae

Infections in Cirrhosis

Changes in the epidemiology and management of bacterial infections in cirrhosis

[Bacterial resistance and antimicrobial therapy in respiratory medicine and intensive care]

Combatting resistance: Understanding multi-drug resistant pathogens in intensive care units